CD274 and neoplasm: With nivolumab alone, in PD-L1+ patients, median PFS: 14.0 months, ORR: 57.5%; in PD-L1− patients, median PFS: 5.3 months, ORR: 41.3%. Combination benefit showed in PD-L1− patients: with combination, ORR: 54.8%, median PFS: 11.2 months; with nivolumab alone, ORR: 41.3%, median PFS: 5.3 months; PD-L1+ cutoff: ≥5% tumor surface expression, Dako 28-8; PD-L1+ prevalence: 23.6%